CLIN LAB 2017
Randox Laboratories will be attending Clin Lab from 6th – 8th April 2017. We look forward to meeting you at Pragati Maidan Exhibition Center, India at Stand No. 9C08, Hall 9.
Randox Laboratories is a global leader in healthcare diagnostics. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective.
JOIN US FOR LIVE DEMONSTRATIONS
Drop by our stand to receive a live demonstration of our latest products including Acusera 24.7, RX imola and RX daytona+. These will take place at Stand No. 9C08, Hall 9 from Thursday – Saturday.
Reduce time spent troubleshooting and analysing QC data with unique access to instantly updated peer group statistics and automatic calculation of Measurement Uncertainty, Sigma Metrics and Total Error all on one centralised platform.
The RX Series is globally renowned for quality and reliability, teamed with one of the most extensive dedicated clinical chemistry test menus on the market you can benefit from real cost savings through the consolidation of routine and specialised tests on a single platform.
The RX series of clinical chemistry analysers combines robust hardware and intuitive software ensuring unrivalled precision and accuracy for results you can trust.
Committed to advancing biochemistry testing for laboratories. We offer a range of high quality reagents that cover routine and novel markers with applications for use on a wide range of clinical chemistry analysers.
Delivering accurate results, Randox QC provides the complete laboratory package combining true third party controls, calibration verification material, interlaboratory data management software and the world’s largest international EQA scheme – RIQAS.
An inflammatory biomarker detects inflammation in the body. Inflammation is not just the immediate, short-term response of the body to an injury or infection. Inflammation within the body can be a long-term, chronic condition resulting in a number of health implications. In diagnostics, measurement of an inflammatory biomarker can not only detect acute inflammation but provide a marker of treatment response.
C-reactive protein (CRP) is an acute phase protein produced by the liver in response to inflammation, infection and tissue injury. CRP is a particularly beneficial inflammatory biomarker as it is detected much faster than other markers in the blood. Levels of CRP increase when inflammation occurs and therefore it can be a significant biomarker in a range of diseases, including the following.
An increasing amount of research exists to suggest CRP is not only a useful, non-specific inflammatory biomarker, but it may have a direct influence on coronary heart disease and cardiac events1. Inflammation can occur when LDL cholesterol builds up in the artery walls causing atherosclerosis. Modifiable risk factors of atherosclerosis include smoking, diabetes, poor diet, high blood pressure and physical inactivity, all factors which subsequently increase the risk of heart attacks, ischemic stroke, peripheral artery disease and even vascular dementia2,3.
Studies have also shown that persistent low levels of CRP can contribute to a person developing CVD. Therefore using high sensitivity CRP as an inflammatory biomarker can detect low levels, helping to predict the likelihood of a patient developing CVD in the future.
Research suggests that inflammation in the body can influence the development of type 2 diabetes. With the ability to be managed through diet and exercise, type 2 diabetes is commonly associated with obesity. Research has shown that excess body fat can cause continuous chronic low-grade inflammation as a result of inflammatory cytokines and increased plasma levels of CRP. As a result, this chronic inflammation has the ability to cause insulin resistance leading to the development of type 2 diabetes4.
A three year study which analysed the bone and joint health of 10,000 patient samples in India has found that inflammatory biomarkers, in particular CRP and ESR (Erythrocyte Sedimentation Rate) were raised in most of the samples compared to any other markers5. Although CRP is a non-specific inflammatory biomarker, it can be used alongside other tests, such as Rheumatoid Factor, to diagnose inflammatory joint diseases such as Rheumatoid Arthritis. Not only will CRP levels be higher due to chronic inflammation, but CRP levels can be monitored to assess levels of inflammation over time, allowing clinicians offer effective treatment.
Chronic Obstructive Pulmonary Disease (COPD)
COPD is a condition associated with inflammation of the lungs and airways. Studies have shown that measuring CRP levels is beneficial to detect exacerbations, when symptoms of COPD get suddenly worse and can last for several days. This is because CRP levels spike when exacerbations happen, causing lung function to deteriorate6.
Neonatal Bacterial Infections
CRP is one of the preferred and frequently used tests in neonatal units when diagnosing suspected bacterial infections, such as neonatal sepsis, in newborns who show signs on infection. Due to delayed synthesis during the inflammatory response, the sensitivity of CRP is lowest during early stages of infection. It is therefore critical that extremely low levels of CRP can be detected during diagnosis to distinguish whether symptoms are related to an infectious or non-infectious condition. This early detection then allows for rapid and appropriate neonatal treatment7.
Inflammatory Bowel Disease
Research suggests that using CRP as an inflammatory biomarker can help distinguish between Inflammatory Bowel Disorder (IBD) and Irritable Bowel Syndrome (IBS)8. Although IBD and IBS have some similarities in symptoms, IBD causes chronic inflammation, whereas IBS is a non-inflammatory condition. Therefore using CRP as a biomarker can allow clinicians to deliver a confident and accurate diagnosis.
For health professionals
Randox Laboratories manufacture a wide range routine and niche biochemistry reagents for use in both a research and clinical setting. With a wide measuring range, the Randox CRP assay will perform excellently to detect levels outside of the healthy range. Also available is a Full Range CRP assay particularly beneficial for use in a neonatal setting, and a High Sensitivity CRP assay, depending on your diagnostic requirements. For more information, please contact: email@example.com
- Shrivastava, A. K., Singh, H.V., Raizada, A. and Singh, S.K. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal. 67, 89-97. (2015)
- American Heart Association. Inflammation and Heart Disease. Available from: https://goo.gl/d82Ynr (2016)
- Harvard Health Publications. What you eat can fuel or cool inflammation. Harvard Health Publications. Available from: https://goo.gl/e8m3El (2007)
- Zeyda, M. and Stulnig, T. M. Obesity, Inflammation, and Insulin Resistance – A Mini-Review. Gerontology 2009; 55:379-386 (2009)
- Mukherjeel, R. Bone and joint health are crucial aspect, usually ignored by Indians. The Times of India. Available from: https://goo.gl/qluzhI (2016)
- Anderson, G. P. COPD, asthma and C-reactive protein. European Respiratory Journal 2006; 27: 874-876. (2006)
- Hofer, N., Zacharias, E., Müller, W. and Resch, B. An update on the Use of C-Reactive Protein in Early-Onset Neonatal Sepsis: Current Insights and New Tasks. Neonatology 2012; 102: 25-36 (2012)
- Silva, P. Two Specific Proteins Allow the Exclusion of IBD in Patients with Irritable Bowel Syndrome. IBD News Today. Available from: https://goo.gl/pxMP53 (2015)
A report has today revealed that almost a third of patients in England and Wales are being given a misdiagnosis following a heart attack, following a study of 243 NHS hospitals, conducted by researchers at Leeds University.
Timely evaluation of patients with chest pain and subsequently suspected heart attack is a major challenge for hospitals around the world, with chest pain typically representing around 5% of all visits to the Emergency Department (ED) and 25% of ED admissions. One of the biggest challenges facing emergency doctors now is how to prioritise people presenting with chest pain – to primarily deal with those suffering from a heart attack, and to be able to move those who are not, to a different ward, to alleviate the pressures of the overrun A&E departments.
Responding to the escalating misdiagnosis crisis in emergency hospitals across the globe, scientists at Randox Laboratories in the UK have developed a test which could help clinicians rule out heart attacks in patients immediately upon arrival at hospital; allowing clinicians to accurately prioritise those who have truly suffered heart attacks.
This Randox test, for Heart-type fatty acid-binding protein (H-FABP), is a highly sensitive biomarker for use in the earlier diagnosis of patients with suspected Acute Myocardial Infarction (AMI), enabling faster “rule-in” and “rule-out”. H-FABP is detectable as early as 30 minutes after chest pain onset, significantly earlier than traditionally used biomarkers such as Troponin or CK-MB , which typically require 6-12 hours to reach detectable concentrations.
Put simply, given that H-FABP is released earlier than traditional biomarkers used in diagnosing a heart attack, an earlier diagnosis is achievable.
A succession of recent international clinical trials have demonstrated that by combining H-FABP, via this new laboratory assay, with the existing tests already used in hospitals for for Troponin I or Troponin T, the sensitivity and negative predictive value for ruling out AMIs is significantly improved.
Growing evidence indicates that even when one of the newer generation of “highly sensitive” Troponin assays is used, utilising the combination of Troponin and H-FABP is superior to Troponin alone.
The value of H-FABP is not just in positive diagnosis – but doctors are beginning to see it as a means of ‘ruling out heart attack’ when a patient presents at A&E with chest pain.
Please do get in touch if you would like to find out more about our H-FABP test, and how this can go a long way in solving the heart attack misdiagnosis crisis, by emailing firstname.lastname@example.org
We’re sure you’ve heard of “Speed Dating”, but what about “Speed Networking”? Randox’s R&D Scientist, Dr. Dwaine Vance tried it out to spread the word about Randox Careers in STEM!
Dr Dwaine Vance visited Omagh High School to represent Randox Careers. He sat down with us, and we discussed the importance of the event. Dr. Vance told us:
On Wednesday the 15th June I represented Randox Careers at a ‘speed networking’ event at Omagh High School. This involved groups of students moving from one employer stand to the next for a 5 minute ‘mini network’. There was two sessions during the morning involving GCSE level pupils. The aim of the ‘speed networking’ event was to provide pupils with opportunities to meet local Northern Irish companies within the Science, Technology, Engineering and Mathematics (STEM) sectors, of which Randox Laboratories play a pivotal role.
We, at Randox, want to inspire students to think about their own career plans and to allow them to gather information about the local job market. By doing this, we’re also giving them the opportunity to be aware of the jobs that are available and the importance of STEM related subjects, as well as letting them see how employers value their other curriculum subjects and their personal skills and attributes. My objective as a employee of Randox was to showcase a range of careers for all abilities within the company with a focus on STEM careers e.g. science and engineering.
The importance of spreading awareness of the opportunities in science and engineering from a young age is imperative, as many students are unaware of the vast range of differentiation in different careerpaths, stemming from one subject or degree class. Dr. Dwaine Vance went on to discuss the events of the networking conference:
As part of each ‘mini network’ I provided students with a brief overview of Randox. Students were given the opportunity to watch videos depicting our expertise and to ask questions about how their interests could be incorporated within Randox. The training department at Randox provided me with pop-up stands, recruitment pathway brochures, merchandise e.g. pens, stopwatches, mug coasters and even Biochip Array Technology key rings!
Overall the students gained a good knowledge of Randox, they were particularly keen to learn about the local and global opportunities available at Randox. In addition, students were keen to know more about the veterinary aspect of Randox. It was comforting to discover that the majority of pupils had previous knowledge of the Randox brand from the press (as we have recently experienced a great boost in brand visibility through Grand national sponsorship), Randox health (television adverts) and Confidante (local radio stations).
The pupils at Omagh High School were keen to ask me about my role within the company and what my day to day roles and responsibilities are. I was happy to provide students with my research and development activities and they were interested to hear that I was involved in the development of a genetic test that aims to predict your future risk of heart disease by investigating your own DNA.
At Randox I am part of a small team of experienced research scientists that are developing a genetic risk prediction test for heart disease and myocardial infarction. This test aims to simultaneously genotype 20 genetics variants that have been previously associated with increased risk of heart disease. This Randox molecular test is in collaboration with leading University academics and will help reduce the burden of heart disease throughout the world by providing an accurate risk assessment of disease so personalised treatment can be provided to those who require it most. To quote Randox Health, “Prevention is better than cure”.
From everyone at the Randox Careers team and from Dr. Dwaine Vance, we’d like to thank Omagh High School for inviting us to attend this incredibly beneficial Speed Networking event, where we feel we have truly impacted the young minds of tomorrow. We look forward to the future of diagnostics, with you!
This British Science Week 2016, the Reagents Team at Randox are celebrating the hard work our Research and Development Team put in every day, to help bring the best quality diagnostic reagents to the market.
We caught up with Emmet Donnelly, Clinical Chemistry R&D Scientist, to explain a bit about what his work involves, and how it’s impacting on global healthcare!
What is your position and what does it involve?
I am a Clinical Analyst on the Clinical Chemistry R&D Team. This role involves the development of new reagents and the improvement of existing reagents. It also involves the transfer and testing of existing chemistries onto new analyser platforms. Troubleshooting and resolving customer queries also forms part of a clinical analyst’s role.
For those of us who aren’t in the industry, can you explain what reagents and assays are?
A reagent is a chemical used to detect the quantity of another component or analyte in a sample (blood or urine), for example a cholesterol reagent contains the necessary chemical make-up to detect the amount of cholesterol in a patient sample.
An assay is the procedure involved in determining the amount of analyte in a sample using a reagent. For example a cholesterol assay involves enzymes within the reagent breaking the cholesterol down into its chemical constituents. These constituents react with other components in the reagent to form a coloured indicator. If this assay is being used on a clinical chemistry analyser, light is passed through the coloured mixture and the amount of light absorbed is proportional to the concentration of analyte in the sample.
How does you work impact on global healthcare?
The diagnostic assays are a vital component in the diagnosis of disease. In order to find out, for example, why a patient is feeling poorly they must first have a blood test to measure all their blood analytes. This will help diagnose the underlying problem and aid in choosing and monitoring the correct treatment for that patient. For example a patient suffering from diabetes must constantly have their glucose levels monitored so that correct doses of insulin can be administered.
What is your favourite Randox product and why?
I like some of the old products like glucose, ALP and cholesterol because they are the tried and tested reagents that are essential for monitoring the health of our vital organs. These always comprise part of the panel of testing to be done when our GP takes a blood sample from us.
I also like the newer reagent products such as the DOA (Drugs of Abuse) reagents. They offer a means of detecting illegal substances in urine samples offering aid to law enforcement.
Immunoturbidimetry methods have become the main technique for performing protein tests. The transition from nephelometry has been cautious but is increasing as laboratories enjoy the comparability and flexibility of immunoturbidimetry.
Immunoturbidimetry and nephelometry both measure the turbidity of a sample to determine the level of an analyte. Upon addition of the assay reagent, antibodies and antigen cluster to form an immune complex that precipitates, increasing the turbidity of the sample. When light is passed through the reaction solution, some light is scattered by the sample, some light is absorbed by the sample and the rest passes through the sample.
Immunoturbidimetry measures the absorbance of the light by the sample, nephelometry measures the light scattered at a fixed angle. The level of analyte is determined by comparison with a calibrator of known concentration.
Immunoturbidimetry is ideal for the detection of proteins, where the analyte concentration is inversely proportional to the transmitted light signal. Historically nephelometry has been more sensitive than conventional immunoturbidimetry. In latex-enhanced immunoturbidimetry, inert microscopic particles enlarge the immune complexes, amplifying the reaction and significantly increasing the sensitivity of the reaction.
Nephelometers are dedicated analysers only capable of performing this type of assay. In addition, they are:
- have high consumable costs
- require highly trained personnel
Immunoturbidimetric tests are carried out on routine biochemistry analysers that are:
- offer longer reagent stability
The main advantage of nephelometry was its sensitivity; however latex-enhanced immunoturbidimetry has closed this gap. Immunoturbidimetric tests are an increasingly accepted alternative to nephelometry for specific protein assays, and studies have shown a close correlation between Randox immunoturbidimetric tests and nephelometry.
If you are interested in running your protein assays on a routine biochemistry analyser, Randox offers a large range of high quality routine and niche protein assays that can be run on most automated analysers, including: Alpha-I acid glycoprotein; alpha-I antitrypsin; anti-streptolysin O; apolipoprotein A-I; apolipoprotein A-II; apolipoprotein B; apolipoprotein C-II; apolipoprotein C-III; apolipoprotein E; ceruloplasmin; complement C3; complement C4; CRP; cystatin C; ferritin; haptoglobin; HbA1c; IgA; IgE; IgG; IgM; lipoprotein (a); microalbumin; myoglobin; rheumatoid factor; transferrin and transthyretin (prealbumin). For more information, download our Reagents Brochure or email: email@example.com.